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Abstract
Background: Dystonia is a movement disorder substantially affecting the quality of life and the ability to work. A
proportion of patients does not respond to first line pharmacotherapy. Deep brain stimulation (DBS) is established
as a primary operative treatment option for severe drug resistant dystonia. We studied dystonia patients treated
with DBS in Finland between the years 2007–2016 to evaluate the use and outcomes of DBS treatment.
Methods: We analysed the hospital records of dystonia patients, who underwent DBS operation during 2007–2016
in Finland. The clinical and technical parameters were recorded as well as preoperative assessments and treatments.
The response to DBS was evaluated retrospectively using the Global Dystonia Rating Scale (GDS).
Results: Out of 585 dB implantations during the study period, 37 were done for dystonia. The clinical response
improved significantly with time in the isolated focal dystonia group, and at 12 months, 22 of 32 patients had
over 50% alleviation of the GDS score. There was only one subclinical intracerebral haemorrhage, and four
infections leading to revision. Speech impairment and limb coordination problems were common stimulation- related
adverse events and were mostly resolved or relieved with the adjustment of stimulation parameters.
Conclusions: DBS seems to be beneficial in dystonia. Although DBS is indicated for dystonia in Finland, the number of
operations did not increase at the same rate as DBS operations in general. DBS appears to be a safe and effective
treatment for focal as well as generalized dystonia.
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Background
Dystonia is a heterogeneous group of disorders, charac-
terized by sustained or intermittent muscle contraction
causing abnormal postures and/or repetitive movements
with unknown aetiology [1]. It is the third most common
movement disorder after essential tremor and Parkinson’s
disease (PD) considerably affecting the quality of life and
ability to work [2].
Currently there are only symptomatic treatments for
dystonia, the most effective being oral treatment with
anticholinergic drugs for generalized dystonia and intra-
muscular botulinum neurotoxin (BoNT) treatment for
focal dystonia, specifically for cervical dystonia, as the
first line treatment [3]. However, several patients do not
respond to BoNT treatment or they lose the effect over
time. Further, the response to oral pharmacotherapy,
used particularly in generalized dystonia, is frequently
inadequate and has several side effects [4].
High-frequency deep brain stimulation (DBS) targeting
bilaterally globus pallidus interna (GPi) has been estab-
lished as effective second line treatment in medically re-
fractory dystonia with severely impaired quality of life
[5–9]. DBS is considered a safe alternative to pallidot-
omy because of its reversibility, lower complication risk
for bilateral procedures and adjustment possibilities [10].
DBS is recommended for generalized and segmental pri-
mary dystonia (level A recommendation) and in
medical-refractory focal dystonia (level B) [10, 11]. In ac-
quired dystonia, DBS is considered less effective, with
the exception of tardive dystonia (level C) [11].
The aim of this study was to evaluate the use and out-
comes of dystonia DBS in Finland. We specially focused
on indications, response and adverse events. Using pa-
tient databases and medical records, we retrospectively
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studied dystonia patients treated with DBS in Finland
between the years 2007–2016.
Methods
We retrospectively analysed the hospital records of pa-
tients, who were diagnosed with dystonia (ICD-10 diag-
noses G24.1-G24.9) and underwent DBS operation
between 1.1.2007 and 31.12.2016 at four out of five DBS
centres in Finland. The data of fifth centre with four pa-
tients was not available. Data of four patients were re-
moved from further analysis. One patient had essential
tremor, one had Tourette syndrome and two patients
were excluded because DBS was removed 1 week after
operation for unknown reasons.
The following data was obtained from the files: patient
age on operation day, maximum follow up time, gender,
the day of DBS operation, re-operations and removal of
DBS, the type of the DBS generator, stimulation parameters
at six and 12 months, the centre where operated, diagnosis
and classification of dystonia, the duration of symptoms be-
fore operation, whether patient had neuropsychological or
psychiatric evaluation, if the patient was able to work after
operation, previous BoNT injections, and whether the
BoNT injections continued after DBS. The device and
stimulation –related perioperative and long-term adverse
events during maximum follow-up time were analysed. Ad-
verse events were categorized into adverse events needing
no action or resolving with programming and serious ad-
verse events requiring hospital admission. No exact target
coordinates were available from patient records.
The motor response to DBS was retrospectively esti-
mated from patient records at six and 12 months after
primary DBS operation using the Global Dystonia Sever-
ity Rating Scale (GDS) [12]. The GDS score was evalu-
ated from different body areas from 0 to 10 (0 being no
dystonia in body area, 1 minimal dystonia, 5 moderate
dystonia, 10 most severe dystonia). The 10 areas tested
were: eyes and upper face; lower face; jaw and tongue;
larynx; neck; shoulder and proximal arm; distal arm and
hand including elbow; pelvis and upper leg; distal leg
and foot; trunk.
Due to non-normal distribution of the data, Mann-
Whitney U -test was used to compare continuous inde-
pendent factors including generator parameter values
and GDS score between groups and Wilcoxon signed
ranks tests for related factors including GDS score in
different time points. Spearman correlation coefficient
was used for correlation analyses between generator pa-
rameters and generator life. Bonferroni correction was
used to account for multiple comparisons. p < 0.05 was
considered statistically significant. Normality testing was
done using the Shapiro-Wilk test. The statistical analysis
was done using SPSS version 24.0 (SPSS Inc., Chicago,
IL, USA).
Results
Thirty-seven patients received DBS because of dystonia
during the years 2007–2016 in Finland with a gradual
annual increase of operations (Additional file 3: Figure S1).
Twenty patients were operated in Helsinki, eight in Tam-
pere, six in Oulu and three in Kuopio university hospitals.
There was a total of 77 operations including primary im-
plantations, generator changes and electrode revisions and
removals. During the years 2007–2016, altogether 585 dB
operations were performed, and dystonia DBS accounted
on average for 6,4% of all DBS operations. The clinical
characteristics of patients are summarized in Table 1.
All focal dystonia patients had isolated cervical dys-
tonia. Of five segmental dystonia patients, one had
cranio-cervical dystonia, three cervico-brachial dystonia,
and one had severe blepharospasm with PISA-syndrome
associated with Parkinson’s disease. One patient had ac-
quired hemidystonia and chorea after stroke. Of general-
ized dystonia patients, one had DYT-1 gene mutation
and the two had positive family history without known
gene mutation. One had neurodegeneration with brain
iron accumulation (NBIA), one had generalized dystonic
tremor and one had acquired tardive dystonia.
Before DBS, eleven patients were considered fit to
work. Nineteen patients were either on a long sick leave
or retired because of sickness and eight patients were re-
tired because of age. Only three patients who were on a
long sick leave with cervical dystonia returned to work
after DBS.
In most cases, neither neuropsychological nor psychi-
atric evaluation was done (25 patients). Preoperative
neuropsychological evaluation was performed in nine
patients. Nine patients received psychiatric evaluation
and five patients received both evaluations. Eleven pa-
tients had previously been diagnosed with depression,
and five of them had preoperative psychiatric evaluation.
Postoperatively, one patient with known depression re-
ported worsening of symptoms. Two patients, with no
diagnosis of depression, reported postoperative signifi-
cant depression. Two patients had preoperative memory
problems, one with NBIA, but were evaluated in neuro-
psychological tests as eligible for DBS. In one patient
cognitive problems worsened after DBS, probably due to
the progression of NBIA. Both patients with previous
cognitive problems had only minor benefit from DBS.
The clinical response as evaluated with GDS score im-
proved significantly between preoperative state and at 6
months after operation in the isolated dystonia group
(p < 0.005, Wilcoxon signed ranks test). The improve-
ment of the GDS score continued at 12 months even
though the difference between six and 12 months was
not significant. At 12 months, the mean reduction in
GDS score was 55% and 22 of 32 patients had over 50%
alleviation. Out of 10 patients with less benefit, 6 had
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mediocre response with stimulation related side effects.
Only 4 patients did not benefit at all, one of them had
NBIA, one had other progressive generalized dystonia
and two had marked side effects with increased stimula-
tion. In the heterogeneous combined dystonia group, the
results varied more and no significant improvement was
seen (Fig. 1a). In the combined dystonia group, the pa-
tient with post-stroke hemidystonia had the best re-
sponse with 75% drop in GDS score. The preoperative
mean GDS was 7,3 ± 2,1 in isolated focal dystonia pa-
tients and 12,5 ± 3,7 in isolated general dystonia patients
reflecting the different clinical phenotype of these
groups. The clinical response improved significantly with
isolated focal dystonia patients, the reduction in GDS
score was 65% between preoperative score and 12
months. A similar non-significant trend was seen with
isolated general dystonia patients (60% reduction in
GDS score) (Fig. 1b).
The clinical response as measured with GDS at 6
and 12 months with isolated dystonia patients did not
differ between age groups under vs. over 50 years,
duration of disease under vs. over 10 years, or pa-
tients with vs. without previously diagnosed depres-
sion (Additional file 1: Table S1).
Table 1 The clinical characteristics of DBS patients
Focal Generalized Segmental Hemidystonia All
(n = 21) (n = 10) (n = 5) (n = 1) (n = 37)
Female 13 (62%) 6 (60%) 3 (60%) 1 (100%) 23 (62%)
Male 8 (38%) 4 (40%) 2 (40%) 14 (38%)
Mean age at operation ± SD, years 51,9 ± 6,6 45,7 ± 19,3 58,9 ± 8,5 25,7 50,3 ± 12,9
Mean follow-up time ± SD, months 19 ± 13 19 ± 16 25 ± 18 96 22 ± 19
Etiology
Idiopathic 21 (100%) 8 (80%) 5 (100%) 34 (92%)
Inherited 1 (10%) 1 (3%)
Acquired 1 (10%) 1 (100%) 2 (5%)
Nervous system pathology
No evidence 21 (100%) 5 (50%) 4 (80%) 30 (81%)
Structural lesion 3 (27%) 1 (100%) 4 (11%)
Degeneration 2 (18%) 1 (20%) 3 (8%)
Clinical characteristics
Associated features
Isolated dystonia 21 (100%) 5 (50%) 4 (80%) 30 (81%)
combined dystonia 1 (100%) 1 (3%)
Other neurological manifestation 5 (50%) 1 (20%) 6 (16%)
Disease course
Stabile 20 (95%) 3 (30%) 2 (40%) 1 (100%) 26 (70%)
Progressive 1 (5%) 7 (70%) 3 (60%) 11 (30%)
Age at onset
3–12 years 5 (50%) 5 (14%)
13–20 years 2 (9%) 1 (10%) 3 (8%)
21–40 years 10 (48%) 1 (10%) 1 (100%) 12 (32%)
over 40 years 9 (43%) 3 (30%) 5 (100%) 17 (46%)
Symptoms before DBS
under 10 years 9 (43%) 5 (50%) 4 (80%) 1 (100%) 19 (51%)
over 10 years 12 (57%) 5 (50%) 1 (20%) 18 (49%)
Working ability before DBS
Fit to work, full-time 7 (33%) 3 (30%) 1 (20%) 11 (30%)
Unable to work 11 (52%) 4 (40%) 2 (40%) 1 (100%) 19 (51%)
Retired because of age 3 (14%) 3 (30%) 2 (40%) 8 (19%)
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All patients had had preoperative brain MRI to calcu-
late electrode trajectory and target. Microelectrode re-
cording (MER) was used in all but the largest centre
(18/38 patients) to pinpoint the target. Postoperatively,
the correct electrode positioning was confirmed by brain
computer tomography in all patients and evaluated by
the operating neurosurgeon in each center.
All patients had primarily non-rechargeable dual-
channel Medtronic Activa PC implantable pulse gener-
ator (IPG), except one patient, who had Medtronic
Kinetra IPG. One patient had primarily temporary pulse
generator that was replaced after 2 months with per-
manent IPG (Activa PC). Quadripolar electrodes were
located bilaterally in GPi, except in one patient with ac-
quired hemidystonia, who had unilateral combined VIM
and GPi electrodes. Contacts were selected according to
mark points based on stereotactic positioning on MRI/
CT fusion scans and/or MER in the beginning and
adjusted later according to clinical response. There was
no significant difference at 12 months in clinical re-
sponse (CGI-C) between patients that had been operated
with and without MER (Additional file 1: Table S1).
Focal dystonia patients had significantly longer mean
duration of generator life at first replacement than gen-
eral dystonia patients (p < 0.05, Mann-Whitney U test)
(Table 2). The number of patients was too small to
statistically compare differences for second and third
generator replacements. Only one rechargeable IPG was
changed during study period, since it depleted com-
pletely because of charging difficulties.
There was a significant inverse correlation between DBS
voltage setting and generator life, but not with pulse width
or frequency at 12 months (r = − 0,566, p < 0.05, Spearman
correlation) (Additional file 4: Figure S2). The mean
stimulation parameters are summarized in Table 3. For all
patients, constant-voltage stimulation was used.
Fig. 1 Box-and-whisker-plot of clinical response estimated by GDS. a The GDS preoperatively and at six and twelve months, respectively, in
isolated and combined dystonia. b The GDS preoperatively and at and twelve months, respectively, in isolated focal and generalized
dystonia. The box represents inter-quartile range, middle line represents median and upper and lower whiskers extend to 95th and 5th
percentile. * = p < 0.005. n.s. = not significant
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There was only one postoperative subclinical intrace-
rebral haemorrhage detected in routine computer tom-
ography control right after the operation. Four patients
developed infection leading to the removal of the device.
Eleven patients (30%) had postoperative antibiotics, in
most cases, the medication was given for mild superficial
infections. One patient’s DBS treatment was discontin-
ued after 2 years because of device-related infection and
patient’s suboptimal commitment to DBS treatment.
Operation-, hardware- and stimulation-related ad-
verse events are summarized in Table 4. The rate of
serious adverse events (SAE) and adverse events (AE)
did not differ between age groups, dystonia types or
patients that had been operated with and without
MER (Additional file 2: Table S2).
Altogether four revisions and seven removal opera-
tions were done in eight patients.
The most common stimulation related adverse events
were dysarthria, impaired upper and lower limb coordin-
ation and impaired balance. DBS programming relieved
often adverse events, even though the adverse events
were not completely resolved in all cases. Adverse events
requiring hospital admission occurred in two patients.
One patient received a percutaneous gastric tube because
of dysphagia, which, however, may also be explained by
the progression of the underlying disease. One patient de-
veloped severe dysarthria because of DBS that did not re-
spond to routine stimulation parameters and needed a
speech communicator. However, the DBS treatment for
dystonia was considered beneficial.
Discussion
DBS is established as an effective treatment for focal,
segmental and generalized dystonia [5–7]. Our study
assessed the Finnish dystonia DBS patients during
2007–2016. The number of dystonia as well as overall
DBS operations has been steadily increasing during the
study period. However, in proportion to the total num-
ber of DBS operations, dystonia related DBS operations
have increased slowly in Finland. No data from other
countries for comparison was available.
DBS alleviated dystonia symptoms in most patients,
and specifically in patients with isolated cervical dystonia
up to 12 months after operation. As compared to the
meta-analysis by Moro et al., where the Burke–Fahn–
Marsden Dystonia Rating Scale motor score improved
65% in isolated dystonia, our patients had slightly less
improvement (55%) [13]. However, the results are not
directly comparable and in the meta-analysis better out-
come was associated with greater dystonia severity. The
Table 3 Stimulation parameters
Focal Generalized All
(n = 17) (n = 9) (n = 31)
Amplitude ± SD (V) 2,9 ± 0,8 3,5 ± 0,7 3,0 ± 1,1
Pulse width ± SD (μs) 280 ± 117 246 ± 125 270 ± 115
Frequency ± SD (Hz) 129 ± 22 123 ± 42 130 ± 30
Stimulation type
Monopolar 12 7 21
Bipolar 3 1 5
Interleave 1 1
Mixed 2 4
Table 4 Adverse events in DBS in dystonic patients
AEa SAEb Resolvedc
Operation and device-related n (%) n (%) n
Antibiotic use due to wound problem 11 (30%) 11
Infection leading to revision 4 (11%) 4
ICH, subclinical 1 (3%) 1
Device-related revision
Intracranial electrode revision 2 (5%) 2
IPG malfunction 2 (5%) 2
IPG dislocation 1 (3%) 1
Contact malfunction 1 (3%) 1
Stimulation-related
Dysarthria 14 (37%) 1 (3%) 7
Dysphagia 4 (11%) 1 (3%) 3
dImpaired upper limb coordination 9 (24%) 6
eImpaired lower limb coordination 7 (19%) 3
Impaired balance 6 (16%) 2
Neck pain 4 (11%) 4
Anxiety / Depression 3 (8%) 2
Fatique 3 (8%) 1
Symptoms complained by single patients: migraine, double vision and vision
blurring, dizziness, and neck pressure, weight loss, hallucinations, tinnitus, and
restlessness. n = 37. aAdverse event. bSerious adverse event. cEvent resolved
completely in study period. dinc. hand tremor, micrographia and stifness. einc.
gait stiffness
Table 2 Generator replacement operations
First Second Third
(n = 22) (n = 5) (n = 2)
Generator life ± SD, months
Focal dystonia 23 ± 5,7 (n = 13) 14 ± 0,2 (n = 2) 6 (n = 1)
Generalized
dystonia
15 ± 6,3 (n = 5) 19 ± 8,0 (n = 3) 26 (n = 1)
All 21 ± 7,2 (n = 22) 17 ± 6,5 (n = 5) 21 ± 7,2 (n = 2)
Type
Medtronic
Activa PC
10 3 1
Medtronic
Activa RC
12 2 1
In addition one patient had reoperation replacing temporary IPG with Permanent one
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majority of our patients had cervical dystonia, with not as
high GDS scores and this might limit relative improve-
ment. Only 4 patients did not benefit from DBS. One had
progressive underlying disease (NBIA) and two had major
side effects with increased stimulation. None of the pa-
tients in our study became completely symptom-free.
Three patients who returned to work had focal dystonia.
The response to DBS remained at 12 months in focal
dystonia patients. According to previous literature, the
response has been reported to evolve in the first months
after surgery, but the long-term effect seems to be sus-
tained at least 5–10 years [9, 14, 15].
The patients in this study were older in comparison to
the meta-analysis by Moro et al., mean age being 50
years compared with 35 years, respectively [13]. As cer-
vical dystonia patients are generally older than general-
ized dystonia patients, the higher proportion of cervical
dystonia probably raises the mean age in this study. The
rate of adverse events did not differ between age groups
in our study. It has been suggested that earlier DBS in-
terventions result in better outcomes [16]. However,
controversial results have been published [17–19]. Also,
younger patients may benefit more from DBS [13, 19].
In our study, the duration of disease or age did not cor-
relate with the clinical response in isolated dystonia.
Interestingly, the only patient with post-stroke hemi-
dystonia had a good response. DBS after stroke remains
a controversial issue, and there is insufficient data to
give general recommendations about it [20].
In this study, about half of patients were referred for
DBS once they were already retired or on long sick leave
because of dystonia. It remains to be seen, whether earl-
ier intervention in suitable dystonic patients may sustain
working ability and reduce social life disabilities.
Present results showed no fatal adverse events or per-
manent damage. Only one subclinical ICH and four in-
fections leading to revision occurred in our cohort.
However, operation and device-related adverse events
that led to hospitalization and/or reoperation occurred
in eight patients. The type of adverse events was similar
to previous studies, but the rate of adverse events was
quite high. The occurrence did not differ between dys-
tonia groups or different centres. Previously, the re-
ported rate of adverse events has varied considerably,
from 5 to 26%, and in dystonia it is higher than in PD,
but comparable to rarer indications like epilepsy and
Tourette syndrome [21]. In our patient material, the
pulse width was higher than in previous studies, thus
this might increase the number of side effects, specific-
ally dysarthria. However, parameter adjustment resolved
or relieved adverse events in most cases. In our cohort,
technical problems including one electrode revision,
were quite common (16%), whereas previously reported
lead fractures did not occur [21–23].
The stimulation-related dysarthria and limb coordin-
ation problems indicated most probably involvement of
internal capsule stimulation. Adverse events were com-
parable to previous studies [24]. The observed propor-
tion of stimulation related speech impairment was quite
high. The result of a recent study suggests that poster-
iorly located active contacts in GPi may give rise to
speech slowing in dystonic patients [25]. Unfortunately,
the exact electrode location could not be defined in this
study. It remains to be seen, whether the use of direc-
tional electrodes can decrease speech problems in pa-
tients with dystonia.
Psychiatric or cognitive adverse events were rare, only
one patient with previously diagnosed depression com-
plained of the worsening of depression and two other
patients reported new onset of depression symptoms
postoperatively.
Many centres consider MER as a gold standard for op-
timal targeting of the DBS lead during operation [26].
However, based on clinical outcome and adverse events,
our results do not suggest superiority of MER over
macrostimulation in dystonia.
The battery life was somewhat lower than in some
previous studies, however, the IPG type was also differ-
ent [17, 27, 28]. Pulse width was on average higher
(270 μs vs. 100–150 μs) while frequency and amplitude
were similar in comparison with previous reports
[29, 30]. Logically voltage amplitude correlated inversely
with battery life, but pulse width did not. Interestingly, the
patients with focal dystonia had significantly longer
battery life than generalized dystonia patients. The
lower voltage values of focal dystonia patients might
cause this, even though stimulation parameters did
not significantly differ.
Rechargeable IPGs have shown to save costs and re-
duce infection risk because of fewer replacements com-
pared with non-rechargeable IPGs [27]. Although 27
operations were done due to battery depletion, only 14
rechargeable IPGs were implanted. Most patients were
satisfied with the rechargeable battery. However, the de-
pendence on daily charging was the reason for some pa-
tients to remain with the non-rechargeable battery.
Being a retrospective uncontrolled observational study,
this study comes with some limitations. The placebo ef-
fect could not be measured. The exact location of elec-
trodes could not be retrieved from patient databases.
Also, the assessment of GDS as well as complication
data was based on patient records and not on systemati-
cal recording. Furthermore, the follow-up was available
for most patients up to 12 months only. The amelior-
ation of motor symptoms was evaluated, but the effects
of reduced non-motor symptoms, such as pain, on GDS
cannot be completely excluded. Moreover, the total
amount of patients was small and especially the groups
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of generalized and segmental dystonia were heteroge-
neous, affecting the statistical analysis.
Conclusion
This study reinforces DBS as an effective treatment op-
tion for dystonia, although symptoms are usually not
completely eliminated. The treatment is generally safe,
and well tolerated after DBS adjustments, but the risk of
adverse events needs to be taken into consideration.
Present results also suggest that MER is not superior to
macrostimulation in dystonia. The number of DBS oper-
ations in dystonia patients has grown slower than in
other DBS indications in Finland. Thus, more emphasis
should be put on increasing awareness of this treatment
option in severe drug resistant dystonia.
Additional files
Additional file 1: Table S1. The clinical response as measured with
GDS in different patient groups in isolated dystonia. The clinical response
as measured with GDS at 6 and 12months with isolated dystonia patients
did not differ between age groups under vs. over 50 years, duration of
disease under vs. over 10 years, patients with vs. without previously
diagnosed depression or that had been operated with and without
MER. (DOCX 13 kb)
Additional file 2: Table S2. The number of patients in different groups
with AE and SAE. The rate of AE and SAE did not differ between age
groups, dystonia types or patients that had been operated with and
without MER. (DOCX 13 kb)
Additional file 3: Figure S1. The annual number of DBS operations in
different dystonia types and total DBS operations in Finland. The number
of DBS operations in dystonia are shown as stacked column graphs and
total number of all DBS operations marked as line. The scale for number
of dystonia DBS is on left and for total DBS operations on right. (TIF 811 kb)
Additional file 4: Figure S2. Scatter plot of generator life. Scatter plot
of generator life versus amplitude (A), pulse width (B) and frequency (C),
All cases were plotted individually. Black line represents regression line.
There was a significant inverse correlation between DBS voltage setting
and generator life, but not with pulse width or frequency at twelve months
(r = − 0,566, p < 0.05, Spearman correlation). (TIF 1504 kb)
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